Palatin Announces Two Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Palatin Technologies, Inc. (NYSE American: PTN) announced two presentations at the virtual ARVO 2021 Annual Meeting, occurring from May 1-7, 2021. The presentations will showcase clinical data for PL9643, a melanocortin agonist, focusing on its potential in treating dry eye disease and ocular inflammation. CEO Carl Spana emphasized the therapeutic promise of melanocortins in inflammatory conditions during the event. Presentations are set for May 1 and May 6, covering efficacy and safety studies and protective effects in ocular disease models, respectively.
- Positive clinical data from Phase 2 study for PL9643 in dry eye disease.
- Presentations highlight significant therapeutic potential of melanocortins in treating inflammation.
- None.
CRANBURY, N.J., April 20, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced two presentations of the Company's melanocortin platform, including PL9643 in dry eye disease, at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, being held virtually May 1-7, 2021.
The presentations highlight the positive clinical data from the Phase 2 clinical study in dry eye disease patients, and the possible utility of melanocortins in the treatment of inflammation and, specifically, ocular inflammation.
"Palatin is excited to present two examples of the significant utility of melanocortins in the treatment for inflammatory conditions. The eye, as well as the gut and kidney, offer a unique environment where melanocortin agonism promotes resolution of inflammation," said Carl Spana, Ph.D., President and CEO of Palatin. "ARVO is the premier global eye and vision forum. We are pleased to showcase Palatin's expertise with melanocortin peptides and how they may provide a safe, well-tolerated, and effective treatment path for inflammatory conditions in the eye."
The presentation details:
Date: | May 1, 2021 |
Time: | 3:15 pm to 4:45 pm Eastern Time |
Session Title: | Dry eye clinical treatments |
Format: | Podium Presentation |
Presenter: | Kenneth Kenyon, MD, treating ophthalmologist and primary investigator |
Title: | "Efficacy and Safety of the Melanocortin Agonist PL9643 in a Phase 2 Study of Subjects with Dry Eye Disease" |
Date: | May 6, 2021 |
Time: | 11:15am – 1:00pm Eastern Time |
Session Title: | Stem cells/gene therapy/transplantation/laser/local therapy |
Format: | Poster Presentation |
Presenter: | John Dodd, PhD, Senior Vice President of Preclinical Research |
Title: | "Protective Effects of 2 Melanocortin Agonists Delivered by Intravitreal Injection in Mouse Models of Retinopathy" |
Both presentations will be available on the Palatin website, www.palatin.com, after the ARVO annual meeting ends on May 7, 2021.
About Melanocortins and Inflammation
The melanocortin receptor ("MCr") system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects.
Many tissues and immune cells located in the eye express melanocortin receptors, empowering our opportunity to directly activate natural pathways to resolve disease inflammation.
About Dry Eye Disease
Dry eye disease is a common inflammatory disease that, left untreated, can become extremely painful and lead to permanent damage to the cornea and vision. Dry eye disease affects the cornea and conjunctiva of the eye resulting in irritation, redness, pain, and blurred vision. It is estimated to affect over 20 million people in the United States. The disease is characterized by insufficient moisture and lubrication in the anterior surface of the eye, leading to dryness, inflammation, pain, discomfort, irritation, diminished quality of life, and in severe cases, permanent vision impairment. Existing therapy for dry eye disease is generally regarded as inadequate by many physicians and patients, and often requires weeks or months to demonstrate activity.
About ARVO
ARVO is the largest and one of the most respected eye and vision research organizations in the world and its members include almost 11,000 researchers from over 75 countries. The members of ARVO cover multiple specialties and consist of both clinical and basic researchers. ARVO advances research worldwide about the visual system and preventing, treating, and curing its disorders.
About Palatin
Palatin researches, develops, and designs novel peptide, peptide mimetic, and small molecule agonist compounds with high selectivity for specific melanocortin receptors. Our current focus is on the design and development of proprietary melanocortin receptor agonists for inflammation and autoimmune conditions, with a focus on ocular diseases. Our therapeutics work by activating endogenous melanocortin pathways to resolve damaging inflammation and allow affected tissues time to heal. Research has shown melanocortin agonists can prevent and reverse inflammation in disease models, including in the eyes and intestine - two of our targeted areas. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com.
Forward-looking Statements
Statements in this press release that are not historical facts, including statements about future expectations of Palatin , such as statements about clinical trial results, potential actions by regulatory agencies including the FDA, regulatory plans, development programs, proposed indications for product candidates, market potential for product candidates, and potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and other regulatory and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.
View original content to download multimedia:http://www.prnewswire.com/news-releases/palatin-announces-two-presentations-at-the-2021-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting-301272303.html
SOURCE Palatin Technologies, Inc.
FAQ
What is the significance of Palatin's presentations at ARVO 2021 for PTN investors?
When are Palatin's presentations at ARVO 2021?
What does PL9643 target in its clinical studies?
